Clinical trial

Bortezomib, Thalidomide, and Dexamethasone Versus Thalidomide and Dexamethasone for Response Rates in Multiple Myeloma Patients: a Retrospective Study

Name

HGM1471-002/24

Description

Retrospective study based on medical records of patients with multiple myeloma, eligible for stem cell transplantation, who received, first-line, the VTD or TD combination.

Trial arms

Trial start

2023-11-20

Estimated PCD

2024-03-20

Trial end

2024-03-30

Status

Recruiting

Treatment

Bortezomib

Bortezomib 1.3mg/m2 SC on days 1,4, 8,11 to the TD scheme for a total of 6 treatment cycles (14,15) (VTD)

Arms:

Bortezomib Group

Other names:

Intervention Group

Size

Primary endpoint

Favorable Response

Post-induction (6 months)

Time to next treatment

Post-induction (2 years)

Eligibility criteria

Inclusion Criteria: * clinical records of patients who were considered eligible for transplant due to their functional status and who were given some treatment strategy comprising a combination of drugs. Exclusion Criteria: * Incomplete clinical records * Clinical records of patients who abandoned treatment or could not continue with the treatment due to economic or distance issues * Clinical records of patients who presented severe sepsis before the beginning of either treatment

Protocol

{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'RETROSPECTIVE'}, 'enrollmentInfo': {'count': 83, 'type': 'ESTIMATED'}}

Updated at

2024-02-28

1 organization

1 product

3 indications

Organization

Hospital General de Mexico

Product

Indication

Indication

Indication